USFDA approves Carvykti for patients with Relapsed or Refractory Multiple Myeloma who have received at least one prior line of therapy

The USFDA has approved Carvykti for patients with Relapsed or Refractory Multiple Myeloma who have received at least one prior line of therapy. This medication is used to treat this specific group of patients. Additionally, cookies are used on the site for analytics, advertising, and to improve user experience. By continuing to use the site, users agree to the use of cookies. To learn more about this and to adjust cookie settings, users can refer to the site’s Cookie Policy.

Source link

error: Content is protected !!